Does the media prefer MAZE or PTCT?

In the previous week, PTC Therapeutics had 16 more articles in the media than Maze Therapeutics. MarketBeat recorded 19 mentions for PTC Therapeutics and 3 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.42 beat PTC Therapeutics' score of 0.57 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is MAZE or COGT more profitable?

Maze Therapeutics' return on equity of -36.62% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -36.62% -31.78% Cogent Biosciences N/A -104.27% -54.64%

Does the media favor MAZE or COGT?

In the previous week, Maze Therapeutics and Maze Therapeutics both had 3 articles in the media. Cogent Biosciences' average media sentiment score of 1.60 beat Maze Therapeutics' score of 1.42 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is SRRK or MAZE more profitable?

Maze Therapeutics' return on equity of -36.62% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Maze Therapeutics N/A -36.62% -31.78%

Does the media prefer SRRK or MAZE?

In the previous week, Scholar Rock had 6 more articles in the media than Maze Therapeutics. MarketBeat recorded 9 mentions for Scholar Rock and 3 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.42 beat Scholar Rock's score of 0.02 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maze Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MAZE or CNTA more profitable?

Maze Therapeutics' return on equity of -36.62% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -36.62% -31.78% Centessa Pharmaceuticals N/A -60.37% -44.17%

Which has better earnings & valuation, CGON or MAZE?

Maze Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,582.80 -$160.99M -$2.33 N/A Maze Therapeutics $167.50M 9.64 -$131.12M -$2.53 N/A

Is CGON or MAZE more profitable?

CG Oncology's return on equity of -23.33% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Maze Therapeutics N/A -36.62% -31.78%

Does the media prefer CGON or MAZE?

In the previous week, CG Oncology had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 4 mentions for CG Oncology and 3 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.42 beat CG Oncology's score of 0.96 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maze Therapeutics (MAZE) Competitors

$29.18 -1.39 (-4.55%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$30.81 +1.63 (+5.60%)

As of 04:02 AM Eastern

Compare

MAZE vs. PTCT, COGT, SRRK, CNTA, and CGON

Should you buy Maze Therapeutics stock or one of its competitors? MarketBeat compares Maze Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maze Therapeutics include PTC Therapeutics (PTCT), Cogent Biosciences (COGT), Scholar Rock (SRRK), Centessa Pharmaceuticals (CNTA), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

How does Maze Therapeutics compare to PTC Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Maze Therapeutics presently has a consensus price target of $66.00, suggesting a potential upside of 126.18%. PTC Therapeutics has a consensus price target of $91.57, suggesting a potential upside of 12.59%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Maze Therapeutics is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

PTC Therapeutics has higher revenue and earnings than Maze Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.64	-$131.12M	-$2.53	N/A
PTC Therapeutics	$1.73B	3.90	$682.64M	-$2.33	N/A

Maze Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Maze Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Maze Therapeutics' return on equity of -36.62% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

In the previous week, PTC Therapeutics had 16 more articles in the media than Maze Therapeutics. MarketBeat recorded 19 mentions for PTC Therapeutics and 3 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.42 beat PTC Therapeutics' score of 0.57 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Maze Therapeutics beats PTC Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Maze Therapeutics compare to Cogent Biosciences?

Maze Therapeutics (NASDAQ:MAZE) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Maze Therapeutics presently has a consensus price target of $66.00, indicating a potential upside of 126.18%. Cogent Biosciences has a consensus price target of $43.73, indicating a potential upside of 16.73%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Maze Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Maze Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Maze Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.64	-$131.12M	-$2.53	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Maze Therapeutics' return on equity of -36.62% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Cogent Biosciences	N/A	-104.27%	-54.64%

In the previous week, Maze Therapeutics and Maze Therapeutics both had 3 articles in the media. Cogent Biosciences' average media sentiment score of 1.60 beat Maze Therapeutics' score of 1.42 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Maze Therapeutics beats Cogent Biosciences on 8 of the 11 factors compared between the two stocks.

How does Maze Therapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Scholar Rock has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

Scholar Rock currently has a consensus target price of $56.00, suggesting a potential upside of 2.38%. Maze Therapeutics has a consensus target price of $66.00, suggesting a potential upside of 126.18%. Given Maze Therapeutics' higher probable upside, analysts plainly believe Maze Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Maze Therapeutics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Maze Therapeutics	$167.50M	9.64	-$131.12M	-$2.53	N/A

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Maze Therapeutics' return on equity of -36.62% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Maze Therapeutics	N/A	-36.62%	-31.78%

In the previous week, Scholar Rock had 6 more articles in the media than Maze Therapeutics. MarketBeat recorded 9 mentions for Scholar Rock and 3 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.42 beat Scholar Rock's score of 0.02 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maze Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Maze Therapeutics beats Scholar Rock on 9 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to Centessa Pharmaceuticals?

Maze Therapeutics (NASDAQ:MAZE) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Maze Therapeutics has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.64	-$131.12M	-$2.53	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

Maze Therapeutics' return on equity of -36.62% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Maze Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Maze Therapeutics had 3 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 3 mentions for Maze Therapeutics and 0 mentions for Centessa Pharmaceuticals. Maze Therapeutics' average media sentiment score of 1.42 beat Centessa Pharmaceuticals' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Maze Therapeutics	Positive
Centessa Pharmaceuticals	Neutral

Maze Therapeutics currently has a consensus target price of $66.00, indicating a potential upside of 126.18%. Centessa Pharmaceuticals has a consensus target price of $41.33, indicating a potential upside of 2.06%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Maze Therapeutics is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

Maze Therapeutics beats Centessa Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

CG Oncology's return on equity of -23.33% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Maze Therapeutics	N/A	-36.62%	-31.78%

CG Oncology presently has a consensus price target of $81.73, suggesting a potential upside of 12.73%. Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 126.18%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Maze Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, CG Oncology had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 4 mentions for CG Oncology and 3 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.42 beat CG Oncology's score of 0.96 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Maze Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,582.80	-$160.99M	-$2.33	N/A
Maze Therapeutics	$167.50M	9.64	-$131.12M	-$2.53	N/A

Summary

Maze Therapeutics beats CG Oncology on 9 of the 16 factors compared between the two stocks.

Get Maze Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MAZE vs. The Competition

Export

Metric	Maze Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.69B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-11.53	20.85	27.13	24.26
Price / Sales	9.64	314.01	589.11	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	3.95	8.49	10.77	6.29
Net Income	-$131.12M	$23.83M	$3.58B	$330.66M
7 Day Performance	-11.14%	-3.56%	-2.10%	-1.32%
1 Month Performance	21.33%	6.31%	3.29%	-0.64%
1 Year Performance	85.39%	48.30%	26.34%	19.08%

Maze Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MAZE Maze Therapeutics	1.9299 of 5 stars	$29.18 -4.5%	$66.00 +126.2%	+93.9%	$1.69B	$167.50M	N/A	121	Positive News
PTCT PTC Therapeutics	2.9955 of 5 stars	$83.31 flat	$91.36 +9.7%	+67.5%	$6.91B	$1.73B	N/A	1,410	Insider Trade High Trading Volume
COGT Cogent Biosciences	2.1125 of 5 stars	$38.69 flat	$43.73 +13.0%	+241.2%	$6.61B	N/A	N/A	80	Positive News
SRRK Scholar Rock	1.7123 of 5 stars	$54.88 flat	$56.00 +2.0%	+46.1%	$6.58B	N/A	N/A	140	Gap Down
CNTA Centessa Pharmaceuticals	0.8267 of 5 stars	$40.50 flat	$41.33 +2.1%	N/A	$6.27B	N/A	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MAZE) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maze Therapeutics (MAZE) Competitors

MAZE vs. PTCT, COGT, SRRK, CNTA, and CGON

How does Maze Therapeutics compare to PTC Therapeutics?

Summary

How does Maze Therapeutics compare to Cogent Biosciences?

Summary

How does Maze Therapeutics compare to Scholar Rock?

Summary

How does Maze Therapeutics compare to Centessa Pharmaceuticals?

Summary

How does Maze Therapeutics compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maze Therapeutics (MAZE) Competitors

MAZE vs. PTCT, COGT, SRRK, CNTA, and CGON

How does Maze Therapeutics compare to PTC Therapeutics?

Do analysts recommend MAZE or PTCT?

Which has stronger earnings and valuation, MAZE or PTCT?

Which has more volatility & risk, MAZE or PTCT?

Is MAZE or PTCT more profitable?

Does the media prefer MAZE or PTCT?

Summary

How does Maze Therapeutics compare to Cogent Biosciences?

Do analysts recommend MAZE or COGT?

Which has more risk and volatility, MAZE or COGT?

Which has stronger valuation & earnings, MAZE or COGT?

Is MAZE or COGT more profitable?

Does the media favor MAZE or COGT?

Summary

How does Maze Therapeutics compare to Scholar Rock?

Which has more volatility and risk, SRRK or MAZE?

Do analysts rate SRRK or MAZE?

Which has higher valuation and earnings, SRRK or MAZE?

Do insiders & institutionals believe in SRRK or MAZE?

Is SRRK or MAZE more profitable?

Does the media prefer SRRK or MAZE?

Summary

How does Maze Therapeutics compare to Centessa Pharmaceuticals?

Which has higher earnings and valuation, MAZE or CNTA?

Is MAZE or CNTA more profitable?

Which has more risk and volatility, MAZE or CNTA?

Do institutionals & insiders have more ownership in MAZE or CNTA?

Does the media refer more to MAZE or CNTA?

Do analysts rate MAZE or CNTA?

Summary

How does Maze Therapeutics compare to CG Oncology?

Is CGON or MAZE more profitable?

Do analysts prefer CGON or MAZE?

Does the media prefer CGON or MAZE?

Which has more volatility & risk, CGON or MAZE?

Do institutionals and insiders hold more shares of CGON or MAZE?

Which has better earnings & valuation, CGON or MAZE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools